Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 184, Issue 4, Pages 616-624Publisher
WILEY
DOI: 10.1111/bjh.15519
Keywords
mantle cell lymphoma; proliferation signature; prognostic biomarker; gene expression analysis; risk group stratification
Categories
Funding
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) [5U01CA157581-05]
- Federal Ministry for Education and Research [FKZ: 01EY1102]
Ask authors/readers for more resources
Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available